Everything below concerns research compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
== Race swap controversy == Psylocke was initially the code name of Elizabeth Braddock, a British woman. However, in a Marvel storyline of 1989, Acts of Vengeance, she was "physically transformed into an Asian woman by a villain seeking to brainwash her and turn her into an elite assassin for a group of ninja warriors." This has been criticized as racially insensitive or stereotypical by multiple fans and critics. For example, Anna Lam calls her new form a "fetishized Asian sex object in the style of the classic Dragon Lady of the 1930s." Chris Claremont, the writer of the story, has said that this transformation was originally simply a disguise but became semi-permanent because most fans embraced it. The artist for the story is Jim Lee, a Korean American. The subsequent storyline of 1993, written by Nicieza, mitigates the issue because subsequently the East Asian Psylocke and the white Psylocke are two distinct women (Kwannon and Betsy Braddock, respectively).
=== Fish === After the fishes were treated with BLCO for 30days, the blood glucose outstandingly elevated, dose dependent of crude oil. Similarly, the degree of total protein concentration and albumin levels increased in proportion to the amount of BLCO. aspartate transaminase (AST) and alanine transaminase (ALT) concentrations rose too. Fishes which are exposed to crude oil get to have PAHs in their tissue and according to Wegwu and Omeodu, they “are activated to highly reactive epoxides by cytochrome P450-containing enzyme systems”. DNA bases automatically respond with these epoxides and point mutations are occurred as a result of it. With regard to glucose levels, if they are extremely high, it means severe oxidation stress in fish. In addition to it, excessive total protein levels of fish specify water imbalance and damage of haemo-concentration. These are resulted by harmful components of crude oil and it would induce damage in cellular membrane, less fluidity in membrane and elimination of cell as well.
Terry Peter Gallagher as Axel Zufo, a fossil fuels billionaire Billy Eichner as Waylen Lemming, a crypto billionaire David Pittu as Ronan Wylde, a banking billionaire Julie Halston as Kitty Munson, a multinational retail billionaire Matthew Laureano as Nate, a victim who is tortured and killed by the Assassin and Jeremy Rev Yolanda as Clara Gardner, a transgender scientist and Mike's best friend Lux Pascal as Clara after the transformation Laura Dreyfuss as Jennifer King Robert Harrington as Jefferson, Byron's bodyguard Kelli O'Hara as Juliana Williams, Meyer's wife Hazel Graye as Juliana after the transformation Kaylee Halko as Joey, the teenage daughter of Meyer and Juliana who has progeria Augusta Liv as Joey after the transformation Kevin Cahoon as Tiger "Tig" Forst, one of Byron and Franny's sons Ray Nicholson as Tig after the transformation Eric Petersen as Gunther Forst, one of Byron and Franny's sons Brandon Gillard as Gunther after the transformation Anthony Rapp as a Scientist who worked for the space colonization division of Byron's corporation Emma Halleen as Bella Grant, a school student who becomes fixated on the "Beauty" Annabelle Wachtel as Ruthie, Bella's best friend who is lamenting a failed nose job Paige McGarvin as Ruthie after the transformation Maria Dizzia as Marcy Grant, Bella's mother Daniel Stewart Sherman as Bella's father Carson Rowland as Conor, an employee of Byron's corporation who administers doses of the "Beauty" Ethan Eisenstein as Conor before the transformation Red Concepcion as Sir Ma'am, a social media influencer Sky Kawai as Sir Ma'am after the transformation
Sources: en.wikipedia.org
In June 1945, the squadron initially flew missions with the 310th Fighter Squadron, often twice a day, using borrowed U.S. aircraft. It received 25 new P-47D-30-RA aircraft in July, marked with the insignia of both the USAAF and Mexican Air Force. The squadron flew more than 90 combat missions, totaling more than 1,900 hours of flight time. It participated in the Allied effort to bomb Luzon and Formosa to push the Japanese out of those islands. It relentlessly attacked the Japanese forces concentrated mainly in Luzon and flew 53 combat missions as part of the U.S. Air Force warfare organization, was specified in the support of the 25th Infantry Division, the Philippine Army, as well as numerous Filipino guerrillas, to open up into the Cagayan valley where the squadron devastated the Japanese defenses on the ground with its bombs. Close support missions consisted mainly of attacking resistance points, apart from these they launched attacks on bases, fortifications, supply routes and machine gun pits. During its fighting in the Philippines, five squadron pilots died (one was shot down, one crashed, and three ran out of fuel and died at sea); and three others died in accidents during training. The pilot Héctor Espinoza Galván was flying together with an American pilot but he ran out of fuel and fell into the ocean; His body was never found. Captain Pablo Ribaz Martínez and Second Lieutenant Guillermo García Ramos were surrounded by a storm, Ribaz Martínez dying while García Ramos survived after being rescued.
== Z-plasty == This is based upon the principle of mobilizing a full segment of skin from an area to the site needing tissue replacement. The flaps are triangularly shaped opposite each other. It can be used in direct excision and closure of a contracted scar to produce a better looking and healing scar. It helps to elongate and break up a linear scar. It also gives a good result in the release of linear contractures. Z-plasty is of paramount importance to the plastic surgeon and a frequently used method in both single multiple forms.
=== Inhibition === NADPH oxidase can be inhibited by apocynin, nitric oxide (NO), and diphenylene iodonium. Apocynin acts by preventing the assembly of the NADPH oxidase subunits. Apocynin decreases influenza-induced lung inflammation in mice in vivo and so may have clinical benefits in the treatment of influenza. Inhibition of NADPH oxidase by NO blocks the source of oxidative stress in the vasculature. NO donor drugs (nitrovasodilators) have therefore been used for more than a century to treat coronary artery disease, hypertension, and heart failure by preventing excess superoxide from deteriorating healthy vascular cells. More advanced NADPH oxidase inhibitors include GKT-831 (Formerly GKT137831), a dual Inhibitor of isoforms NOX4 and NOX1 which was patented in 2007. The compound was initially developed for Idiopathic pulmonary fibrosis and obtained orphan drug designation by the FDA and EMA at end of 2010.
== History == Streptomycin was first isolated on October 19, 1943, by Albert Schatz, a PhD student in the laboratory of Selman Abraham Waksman at Rutgers University in a research project funded by Merck and Co. Waksman and his laboratory staff discovered several antibiotics, including actinomycin, clavacin, streptothricin, streptomycin, grisein, neomycin, fradicin, candicidin, and candidin. Of these, streptomycin and neomycin found extensive application in the treatment of numerous infectious diseases. Streptomycin was the first antibiotic cure for tuberculosis (TB). In 1952 Waksman was the recipient of the Nobel Prize in Physiology or Medicine in recognition "for his discovery of streptomycin, the first antibiotic active against tuberculosis". Waksman was later accused of playing down the role of Schatz who did the work under his supervision, claiming that Elizabeth Bugie had a more important role in its development. Schatz sued both Dr. Waksman and the Rutgers Research and Endowment Foundation, wanting to be given credit as co-discover and to receive the royalties for the streptomycin. By the end of the settlement, Waksman would receive a 10% royalty, while Schatz got 3% and compensation for his missed royalties. The rest of the lab shared the remaining 7% of the royalties, in which Bugie received 0.2%. Bugie was pursuing a master's degree in Waksman's lab at Rutgers University at this time. Prior to this, she received her bachelor's degree in microbiology at New Jersey College for Women.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.